A PROSPECTIVE, MULTICENTER PHASE II STUDY EVALUATING PREDICTIVE FACTORS FOR LENALIDOMIDE TREATMENT RESPONSE IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2013
At a glance
- Drugs Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms Le.P.Re
- 21 Jul 2012 Celgene Corporation added as associations as reported in the European Clinical Trials Database record.
- 21 Jul 2012 Actual end date (16 Jul 2012) added as reported by European Clinical Trials Database record.
- 16 Jul 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.